← SynDRA
SAMOTOLISIB
SynDRA canonical compound SYN0039407 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AKT1 | MTOR |
|---|
| Mechanism of action | mTOR inhibitor | PI3K inhibitor |
|---|
All known targets
- MTOR
- PIK3CA
- PIK3CB
- PIK3CD
- PIK3CG
- AKT1
- PIK3R1
- PIK3R2
- PIK3R3
- PIK3R5
Mechanisms of action (all sources)
- MTOR inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
- PIK3R1 INHIBITOR
- PIK3CB INHIBITOR
- PIK3CG INHIBITOR
- PIK3CA INHIBITOR
- PIK3R2 INHIBITOR
- PIK3CD INHIBITOR
- PIK3R5 INHIBITOR
- PIK3R3 INHIBITOR
- PI3K inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CA
- PIK3CB
- PIK3CD
- PIK3CG
- HDAC6
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- LY-3023414
- LY3023414
- LY 3023414
- GTPL8918
- Samotolisib [USAN]
- Samotolisib (USAN)
- C88817F47Y
- 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one
- 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-
- 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
- (S)-8-(5-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
- UNII-C88817F47Y
- example 1 [US8440829]
- 2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(2S)-2-methoxypropyl]-3-methyl-
- SAMOTOLISIB [INN]
- SAMOTOLISIB [WHO-DD]
- CHEMBL4297181
- SCHEMBL10321700
- BCP16703
- EX-A2728
- NSC789968
- NSC800994
- s8322
- WHO 10889
- ZINC143116580
- AT19320
- CCG-264765
- CS-5361
- DB12167
- NSC-789968
- NSC-800994
- NCGC00485487-01
- AC-30224
- HY-12513
- PI3K/MTOR INHIBITOR LY3023414
- A16126
- D11501
- A856859
- LY-3023414;LY 3023414
Look up SAMOTOLISIB in the interactive SynDRA portal →